Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: The genetics of hypertension associated treatment study
Richard Sherva, Charles E. Ford, John H. Eckfeldt, Barry R. Davis, Eric Boerwinkle, Donna K. Arnett
Dive into the research topics of 'Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: The genetics of hypertension associated treatment study'. Together they form a unique fingerprint.